Drug
DFP-13318 clinical trials
- studies test it
- 5
- open now
- 1
- in phase 3
- 0
- first study started
- 2016
Keep track of what changes. Save the DFP-13318 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 4
National Cancer Institute (NCI) (2) · Institut Curie (2) · ProLynx LLC (1)
Often tested with
Tested in the same studies.
Pegylated SN-38 Conjugate PLX038 (5) · Rucaparib (1) · Tuvusertib (1)
Studies
Open first, then newest update. How each study uses DFP-13318 is read from its arms, and is right about nine times in ten.
Testing it · 5
- PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsRecruitingPhase 1/2National Cancer Institute (NCI)NCT06161519Written as PLX038
- PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04209595Written as PLX038
- A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid TumorsTerminatedPhase 1Institut CurieNCT06337630Written as PLX038 + Tuvusertib
- A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast CancerTerminatedPhase 2Institut CurieNCT06162351Written as PLX038
- A Phase I Study of PLX038 in Patients With Advanced Solid TumorsCompletedPhase 1ProLynx LLCNCT02646852Written as PLX038
Codes
What other systems call DFP-13318 · ClinicalTrials.gg INT017374
- UNII (FDA) NA676B3565DFP-13318One source FDA
- NCI Thesaurus C125243Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NA676B3565 | DFP-13318 | One source FDA |
| NCI Thesaurus | C125243 | Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.